Abstract/References

This meta-analysis aimed to investigate the impact of pretreatment quality of life (QoL) on overall survival (OS) in patients with hematological malignancies. The observational studies with relationship between QoL and OS in patients undergoing either hematopoietic stem cell transplantation (HSCT) or chemotherapy were collected. Stratification by treatment was performed to examine the association between QoL and OS. Six articles were included in the analysis. Overall, significant associations with OS were observed for global QoL (hazard ratio [HR] = 1.04, 95% confidence interval [CI] = 1.01–1.08), physical QoL (HR = 1.06, 95% CI:1.02–1.10), and social QoL (HR = 1.02, 95% CI: 1.00–1.03). When stratified by treatment, HSCT showed significant associations between OS and both global QoL (HR = 1.05, 95% CI:1.00–1.11) and physical QoL (HR = 1.03, 95% CI:1.00–1.06). For chemotherapy, significant associations were also observed between OS and global QoL (HR = 1.04, 95% CI:1.00–1.09), physical QoL (HR = 1.08, 95% CI:1.00–1.17), role QoL (HR = 1.02, 95% CI:1.00–1.04), and social QoL (HR = 1.02, 95% CI:1.00–1.04). No significant associations were observed regarding emotional QoL, which was only analyzed in HSCT. The factors influencing OS may vary depending on the treatment, emphasizing the importance of recognizing QoL from the pretreatment stage.

1. Buffart LM, De Backer IC, Schep G, Vreugdenhil A, Brug J, Chinapaw MJM.　Fatigue mediates the relationship between physical fitness and quality of life in cancer survivors.　J Sci Med Sport, 16:99-104, 2013.

2. Duan L, Cui H, Zhang W, Wu S.　Symptoms and experiences of frailty in lung cancer patients with chemotherapy:A mixed-method approach.　Front Oncol, 12:1019006, 2022.

3. Morishita S, Kaida K, Yamauchi S, et al.　Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients.　Support Care Cancer, 21:2161-2169, 2013.　

4. Polat K, Karadibak D, Güç ZGS, Yavuzşen T, Öztop İ.　The Relationship between Exercise Capacity and Muscle Strength, Physical Activity, Fatigue and Quality of Life in Patients with Cancer Cachexia.　Nutr Cancer, 76:55-62, 2024.　

5. Morishita S, Hirabayashi R, Tsubaki A, et al.　Relationship between balance function and QOL in cancer survivors and healthy subjects.　Medicine (Baltimore), 100:e27822, 2021.

6. Osaki K, Morishita S, Takami S, et al.　Quality of life of patients with hematological malignancies and factors affecting health state utility values.　Support Care Cancer, 30:5319-5327, 2022.

7. Su M, Yao N, Shang M, et al.　Frailty and its association with health-related quality of life among older cancer patients:an evidence-based study from China.　Health Qual Life Outcomes, 20:124, 2022.

8. Aguiñaga S, Ehlers DK, Cosman J, Severson J, Kramer AF, McAuley E.　Effects of physical activity on psychological well-being outcomes in breast cancer survivors from prediagnosis to posttreatment survivorship.　Psychooncology, 27:1987-1994, 2018.

9. Lin YY, Wu YC, Rau KM, Lin CC.　Effects of physical activity on the quality of life in taiwanese lung cancer patients receiving active treatment or off treatment.　Cancer Nurs, 36:E35-41, 2013.

10. Manneville F, Rotonda C, Conroy T, Bonnetain F, Guillemin F, Omorou AY.　The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer.　Cancer, 124:797-806, 2018.

11. Bellali T, Manomenidis G, Meramveliotaki E, Minasidou E, Galanis P.　The impact of anxiety and depression in the quality of life and psychological well-being of Greek hematological cancer patients on chemotherapy.　Psychol Health Med, 25:201-213, 2020.

12. Poort H, Jacobs JM, Pirl WF, Temel JS, Greer JA.　Fatigue in patients on oral targeted or chemotherapy for cancer and associations with anxiety, depression, and quality of life.　Palliat Support Care, 18:141-147, 2020.

13. Li Q, Lin Y, Qiu Y, Gao B, Xu Y.　The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer:a cross-sectional study.　Eur J Oncol Nurs, 18:425-435, 2014.

14. Ramasubbu SK, Pasricha RK, Nath UK, Rawat VS, Das B.　Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital.　Cancer Rep (Hoboken), 4:e1312, 2021.

15. Schwartz RM, Bevilacqua KG, Alpert N, et al.　Educational Attainment and Quality of Life among Older Adults before a Lung Cancer Diagnosis.　J Palliat Med, 23:498-505, 2020.

16. Zang Y, Qiu Y, Sun Y, Fan Y.　Baseline functioning scales of EORTC QLQ-C30 predict overall survival in patients with gastrointestinal cancer:a meta-analysis.　Qual Life Res, 33:1455-1468, 2024.

17. De Aguiar SS, Bergmann A, Mattos IE.　Quality of life as a predictor of overall survival after breast cancer treatment.　Qual Life Res, 23:627-637, 2014.

18. Hiratsuka Y, Kim YJ, Suh SY, et al.　The association between changes in symptoms or quality of life and overall survival in outpatients with advanced cancer.　Ann Palliat Med, 11:2338-2348, 2022.

19. Kypriotakis G, Vidrine DJ, Francis LE, Rose JH.　The longitudinal relationship between quality of life and survival in advanced stage cancer.　Psychooncology, 25:225-231, 2016.

20. Mackay TM, Latenstein AEJ, Sprangers MAG, et al.　Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer:A Multicenter Cohort Analysis.　J Natl Compr Canc Netw, 18:1354-1363, 2020.

21. McGarrah P, Hubbard J, Novotny PJ, et al.　Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer.　Cancer Control, 30:10732748231185047, 2023.

22. Monteiro MR, Nunes NCC, Crespo J, et al.　Patient-centered Outcomes in Breast Cancer:Description of EQ-5D-5L and EORTC-QLQ-BR23 Measurements in Real-world Data and Their Association With Survival.　Clin Oncol (R Coll Radiol), 34:608-616, 2022.

23. Ediebah DE, Quinten C, Coens C, et al.　Quality of life as a prognostic indicator of survival:A pooled analysis of individual patient data from canadian cancer trials group clinical trials.　Cancer, 124:3409-3416, 2018.

24. Gotay CC, Kawamoto CT, Bottomley A, Efficace F.　The prognostic significance of patient-reported outcomes in cancer clinical trials.　J Clin Oncol, 26:1355-1363, 2008.

25. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group.　Preferred reporting items for systematic reviews and meta-analyses:the PRISMA Statement.　Open Med, 3:e123-130, 2009.

26. Page MJ, McKenzie JE, Bossuyt PM, et al.　The PRISMA 2020 statement:an updated guideline for reporting systematic reviews.　Syst Rev, 10:89, 2021.

27. Aaronson NK, Ahmedzai S, Bergman B, et al.　The European Organization for Research and Treatment of Cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology.　J Natl Cancer Inst, 85:365-376, 1993.

28. Ware JE, Sherbourne CD.　The MOS 36-item short-form health survey (SF-36).　I. Conceptual framework and item selection.　Med Care, 30:473-483, 1992.

29. Cella DF, Tulsky DS, Gray G, et al.　The Functional Assessment of Cancer Therapy scale:development and validation of the general measure.　J Clin Oncol, 11:570-579, 1993.

30. Ottawa Hospital Research Institute.　Accessed May 30, 2024.　https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

31. Hamilton BK, Law AD, Rybicki L, et al.　Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.　Bone Marrow Transplant, 50:1235-1240, 2015.　doi:10.1038/bmt.2015.122

32. Kurosawa S, Yamaguchi T, Mori A, et al.　Prognostic Impact of Pretransplantation Quality of Life and Its Post-Transplantation Longitudinal Change after Allogeneic Hematopoietic Cell Transplantation:A Prospective Study That Administered the Short-Form Health Survey (SF-12) and EuroQol 5.　Transplant Cell Ther, 27:935.e1-935.e9, 2021.

33. Huang H, Datye A, Fan M, et al.　Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma:Analysis of 1239 patients from the GOYA study.　Cancer Med, 11:3312-3322, 2022.

34. Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, Cavallin-Stahl E.　Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma:a Nordic Lymphoma Group Trial.　Med Oncol, 18:85-94, 2001.

35. Jung HA, Park S, Cho JH, et al.　Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP:results from a prospective cohort study.　Ann Hematol, 91:1747-1756, 2012.

36. Lindberg Å, Eskelund CW, Albertsson-Lindblad A, et al.　Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma:The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.　Hematol Oncol, 40:22-30, 2022.

37. Hui D.　Prognostication of Survival in Patients With Advanced Cancer:Predicting the Unpredictable? Cancer Control, 22:489-497, 2015.

38. Mahesh PA, Archana S, Jayaraj BS, et al.　Factors affecting 30-month survival in lung cancer patients.　Indian J Med Res, 136:614-621, 2012.

39. Mariotto AB, Noone AM, Howlader N, et al.　Cancer survival:an overview of measures, uses, and interpretation.　J Natl Cancer Inst Monogr, 2014:145-186, 2014.

40. Ahmed T, Lycan T, Dothard A, et al.　Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer.　Clin Lung Cancer, 21:e286-e293, 2020.

41. Bowden JCS, Williams LJ, Simms A, et al.　Prediction of 90 Day and Overall Survival after Chemoradiotherapy for Lung Cancer:Role of Performance Status and Body Composition.　Clin Oncol (R Coll Radiol), 29:576-584, 2017.

42. Dziggel L, Gebauer N, Bartscht T, Schild SE, Rades D.　Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer.　Anticancer Res, 38:2391-2394, 2018.

43. Keane N, Fragkos KC, Patel PS, et al.　Performance Status, Prognostic Scoring, and Parenteral Nutrition Requirements Predict Survival in Patients with Advanced Cancer Receiving Home Parenteral Nutrition.　Nutr Cancer, 70:73-82, 2018.

44. Nguyen T, Bartscht T, Schild SE, Rades D.　Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer.　Anticancer Res, 40:1665-1668, 2020.

45. Afram G, Gran C, Borg Bruchfeld J, et al.　Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma:Real-life outcomes of daratumumab treatment.　Eur J Haematol, 105:196-202, 2020.

46. Arboe B, Halgren Olsen M, Duun-Henriksen AK, et al.　Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation.　Leuk Lymphoma, 59:1153-1162, 2018.

47. Corry J, Smith JG, Wirth A, Quong G, Liew KH.　Primary central nervous system lymphoma:age and performance status are more important than treatment modality.　Int J Radiat Oncol Biol Phys, 41:615-620, 1998.

48. Saraceni F, Labopin M, Forcade E, et al.　Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%:A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).　Cancer Med, 10:23-33, 2021.

49. Inoue J, Morishita S, Okayama T, et al.　Impact of quality of life on mortality risk in patients with esophageal cancer:a systematic review and meta-analysis.　Esophagus, 21:270-282, 2024.　

50. Okayama T, Suzuki K, Morishita S, et al.　Pretreatment quality of life and survival in patients with lung cancer:a systematic review and meta-analysis [published correction appears in BMC Cancer.　2024 Apr 25;24:529.].　BMC Cancer, 24:495, 2024.

51. Ishiyama H, Kawakami S, Sekiguchi A, et al.　Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy.　Sci Rep, 12:2387, 2022.

52. Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L.　Quality of life versus length of life considerations in cancer patients:A systematic literature review.　Psychooncology, 28:1367-1380, 2019.

53. Mishra A, Pidala J, Thapa R, et al.　Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients.　Bone Marrow Transplant, 56:2897-2903, 2021.

54. Fukushima T, Nakano J, Ishii S, et al.　Influence of Hemoglobin Level on Muscle and Physical Functions, Activities of Daily Living, and Quality of Life in Patients With Hematological Malignancies.　Integr Cancer Ther, 18:1534735419842196, 2019.　

55. Morishita S, Kaida K, Tanaka T, et al.　Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation.　Support Care Cancer, 20:3161-3168, 2012.

56. Xiao DY, Luo S, O’Brian K, et al.　Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.　Am J Hematol, 91:1002-1007, 2016.

57. Klepin HD, Tooze JA, Pardee TS, et al.　Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.　J Am Geriatr Soc, 64:1988-1995, 2016.

58. Liu MA, DuMontier C, Murillo A, et al.　Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.　Blood, 134:374-382, 2019.

59. Morishita S, Kaida K, Yamauchi S, et al.　Relationship of physical activity with physical function and health-related quality of life in patients having undergone allogeneic haematopoietic stem-cell transplantation.　Eur J Cancer Care (Engl)., 26, 2017.

60. Eiser C.　Beyond survival:quality of life and follow-up after childhood cancer.　J Pediatr Psychol, 32:1140-1150, 2007.

61. Else M, Smith AG, Cocks K, et al.　Patients’ experience of chronic lymphocytic leukaemia:baseline health-related quality of life results from the LRF CLL4 trial.　Br J Haematol, 143:690-697, 2008.

62. Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R.　Quality of life of patients with chronic lymphocytic leukemia:results of a longitudinal investigation over 1 yr.　Eur J Haematol, 72:381-389, 2004.

63. Braamse AMJ, Gerrits MMJG, van Meijel B, et al.　Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies.　Bone Marrow Transplant, 47:757-769, 2012.

64. Ueno NT, Ito TD, Grigsby RK, Black MV, Apted J.　ABC conceptual model of effective multidisciplinary cancer care.　Nat Rev Clin Oncol, 7:544-547, 2010.